NIOWAVE reports APVO stake and $8 warrants

NIOWAVE, INC., a ten percent owner of Aptevo Therapeutics Inc., filed an initial ownership report on Form 3.

Rhea-AI Filing Summary

NIOWAVE, INC., a ten percent owner of Aptevo Therapeutics Inc., filed an initial ownership report on Form 3. The filing shows direct ownership of 98,522 shares of Common Stock. It also lists a warrant to buy 53,201 shares of Common Stock at an exercise price of $8.00 per share, expiring on May 25, 2031.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider NIOWAVE, INC.

Role 10% Owner

Type	Security	Shares	Price	Value
holding	Warrant (right to buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Warrant (right to buy) — 53,201 contracts (Direct); Common Stock — 98,522 shares (Direct)

Key Figures

Common shares owned: 98,522 shares Warrant underlying shares: 53,201 shares Warrant exercise price: $8.00 per share +2 more

5 metrics

Common shares owned 98,522 shares Directly owned Common Stock reported on Form 3

Warrant underlying shares 53,201 shares Underlying Common Stock for reported warrant

Warrant exercise price $8.00 per share Exercise price of warrant to buy Common Stock

Warrant expiration May 25, 2031 Expiration date of warrant position

Holding entries 2 entries One Common Stock position and one warrant position

Key Terms

Form 3, ten percent owner, Warrant (right to buy), exercise price, +1 more

5 terms

Form 3 regulatory

"filed an initial ownership report on Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

ten percent owner regulatory

"NIOWAVE, INC., a ten percent owner of Aptevo Therapeutics Inc."

Warrant (right to buy) financial

"Warrant (right to buy) with underlying Common Stock shares"

exercise price financial

"a warrant to buy 53,201 shares at an exercise price of $8.00"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"the warrant expires on May 25, 2031"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does NIOWAVE, INC.'s Form 3 filing for APVO show?

The Form 3 shows NIOWAVE, INC. as a ten percent owner of Aptevo Therapeutics Inc., holding 98,522 Common shares and a warrant to purchase 53,201 additional shares at $8.00 per share, expiring on May 25, 2031.

How many Aptevo Therapeutics (APVO) shares does NIOWAVE, INC. own?

NIOWAVE, INC. directly owns 98,522 shares of Aptevo Therapeutics Common Stock. This share count reflects its reported beneficial ownership as a ten percent owner in the Form 3 initial ownership statement filed with regulators.

What warrants related to APVO does NIOWAVE, INC. report on Form 3?

NIOWAVE, INC. reports a warrant described as a right to buy 53,201 shares of Aptevo Therapeutics Common Stock. The warrant carries an exercise price of $8.00 per share and an expiration date of May 25, 2031.

What is the exercise price and expiration date of NIOWAVE's APVO warrant?

The reported warrant held by NIOWAVE, INC. on Aptevo Therapeutics has an exercise price of $8.00 per share. According to the Form 3, the warrant expires on May 25, 2031, defining the period during which it can be exercised.

Is the NIOWAVE, INC. Form 3 for APVO a record of a new trade?

The Form 3 is an initial ownership report, not a trade confirmation. It lists NIOWAVE, INC.’s existing holdings in Aptevo Therapeutics, including 98,522 Common shares and a warrant for 53,201 shares, rather than reporting a new purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 11:44 AM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

NIOWAVE, INC.

(Last) (First) (Middle)

1012 N. WALNUT STREET

(Street)

LANSING MICHIGAN 48906

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/25/2026

3. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	98,522	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (right to buy)	05/25/2026	05/25/2031	Common Stock	53,201	$8	D

Explanation of Responses:

	Jaime A Lerma	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)